drugset / Trial / NCT00099736

Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant

NCT00099736

Phase 3 Completed 696 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.

Timeline

Start
2003-05-07
Primary completion
2005-09-19
Completion
2005-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide
Subject Fingolimod Small molecule 2.5 mg
Subject Fingolimod Small molecule 5 mg
Subject MMF 2 g + full-dose Neoral (FDN) + corticosteroids Unknown 2 g

Indications

No indication recorded.